Impact of Intrapartum Oral Azithromycin on the Acquired Macrolide Resistome of Infants' Nasopharynx: A Randomized Controlled Trial.

Abdoulie Bojang ORCID logo ; Sarah L Baines ; Bully Camara ORCID logo ; Romain Guerillot ; Liam Donovan ; Raquel Sánchez Marqués ; Ousman Secka ; Umberto D'Alessandro ORCID logo ; Christian Bottomley ORCID logo ; Benjamin P Howden ; +1 more... Anna Roca ORCID logo ; (2020) Impact of Intrapartum Oral Azithromycin on the Acquired Macrolide Resistome of Infants' Nasopharynx: A Randomized Controlled Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 71 (12). pp. 3222-3225. ISSN 1058-4838 DOI: 10.1093/cid/ciaa609
Copy

UNLABELLED: In a post hoc analysis of samples from an intrapartum azithromycin randomized clinical trial, we found that children whose mothers had been treated with the drug had higher prevalence of macrolide-resistance genes msr(A) and ermC at 28 days but not at 12 months. The 2 genes were positively associated in the nasopharynx. CLINICAL TRIALS REGISTRATION: NCT1800942.
Item Type Article
Elements ID 148017
Date Deposited 24 Mar 2021 14:51

Explore Further

picture_as_pdf
Impact of Intrapartum Oral Azithromycin on the Acquired Macrolide Resistome of Infants Nasopharynx A Randomized Controlled T.pdf
subject
Published Version
Available under Creative Commons: Attribution 3.0
View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL Data Cite XML EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads